Original language | English (US) |
---|---|
Pages (from-to) | 1484-1488 |
Number of pages | 5 |
Journal | American journal of respiratory and critical care medicine |
Volume | 196 |
Issue number | 11 |
DOIs | |
State | Published - Dec 1 2017 |
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
- Pulmonary and Respiratory Medicine
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: American journal of respiratory and critical care medicine, Vol. 196, No. 11, 01.12.2017, p. 1484-1488.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Cardiac morphometry on computed tomography and exacerbation reduction with β-blocker therapy in chronic obstructive pulmonary disease
AU - Bhatt, Surya P.
AU - Vegas-Sánchez-Ferrero, Gonzalo
AU - Rahaghi, Farbod N.
AU - MacLean, Erick S.
AU - Gonzalez-Serrano, German
AU - Come, Carolyn E.
AU - Kinney, Gregory L.
AU - Hokanson, John E.
AU - Budoff, Matthew J.
AU - Cuttica, Michael J.
AU - Wells, J. Michael
AU - Estépar, Raúl San José
AU - Washko, George R.
N1 - Funding Information: Supported by awards R01 HL089897, R01 HL089856, R01HL116473, and R01HL116931 from the NHLBI. S.P.B. is supported by National Institutes of Health K23 grant K23HL133438. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion, and GlaxoSmithKline. Acknowledgment: The authors thank Alejandro A. Diaz, M.D., M.P.H. (Brigham and Women’s Hospital), Ravi Kalhan, M.D. (Northwestern University), and Mark T. Dransfield, M.D. (University of Alabama at Birmingham) for their valuable input. Funding Information: Supported by awards R01 HL089897, R01 HL089856, R01HL116473, and R01HL116931 from the NHLBI. S.P.B. is supported by National Institutes of Health K23 grant K23HL133438. The COPDGene project is also supported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, Sunovion, and GlaxoSmithKline.
PY - 2017/12/1
Y1 - 2017/12/1
UR - http://www.scopus.com/inward/record.url?scp=85038118069&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038118069&partnerID=8YFLogxK
U2 - 10.1164/rccm.201702-0399LE
DO - 10.1164/rccm.201702-0399LE
M3 - Letter
C2 - 28441027
AN - SCOPUS:85038118069
SN - 1073-449X
VL - 196
SP - 1484
EP - 1488
JO - American Review of Respiratory Disease
JF - American Review of Respiratory Disease
IS - 11
ER -